INTRODUCTION: The immunosuppressive enzyme, indoleamine 2,3 dioxygenase (IDO), is overexpressed in many different tumor types including breast cancer. IDO inhibitors synergize with chemotherapy in breast cancer murine models. Characterizing IDO expression in breast cancer could define which patients receive IDO inhibitors. This study analyzed IDO protein expression in 203 breast cancer cases. The relationship between IDO, overall survival (OS), disease-specific survival (DSS), clinicopathologic, molecular, and immune tumor infiltrate factors was evaluated. METHODS: Expression of IDO, estrogen receptor (ER), progesterone receptor (PR), human epithelial receptor 2, cytokeratin 5/6, epithelial growth factor receptor, phosphorylated AKT, neoangiogenesis, nitrogen oxide synthetase 2 (NOS2), cyclooxygenase 2 (COX2), FoxP3, CD8, and CD11b on archival breast cancer tissue sections was evaluated by immunohistochemistry. Associations between IDO and these markers were explored by a univariate and multivariate analysis. Survival was analyzed using Kaplan-Meier (OS) and Wilcoxon two-sample (DSS) tests. RESULTS: IDO expression was higher in ER+ tumors compared to ER- tumors. IDO was lower in those with higher neoangiogenesis. OS was better in ER+ patients with high IDO expression. DSS was better in node-positive patients with high IDO expression. IDO activity positively correlates with NOS2. COX2 as positively correlated with IDO on univariate but not multivariate analysis. There was a trend toward greater numbers of CD11b+ cells in IDO-low tumors. CONCLUSIONS: IDO protein expression is lower in ER- breast tumors with greater neoangiogenesis. Future clinical trials evaluating the synergy between IDO inhibitors and chemotherapy should take this finding into account and stratify for ER status in the trial design.
INTRODUCTION: The immunosuppressive enzyme, indoleamine 2,3 dioxygenase (IDO), is overexpressed in many different tumor types including breast cancer. IDO inhibitors synergize with chemotherapy in breast cancermurine models. Characterizing IDO expression in breast cancer could define which patients receive IDO inhibitors. This study analyzed IDO protein expression in 203 breast cancer cases. The relationship between IDO, overall survival (OS), disease-specific survival (DSS), clinicopathologic, molecular, and immune tumor infiltrate factors was evaluated. METHODS: Expression of IDO, estrogen receptor (ER), progesterone receptor (PR), human epithelial receptor 2, cytokeratin 5/6, epithelial growth factor receptor, phosphorylated AKT, neoangiogenesis, nitrogen oxide synthetase 2 (NOS2), cyclooxygenase 2 (COX2), FoxP3, CD8, and CD11b on archival breast cancer tissue sections was evaluated by immunohistochemistry. Associations between IDO and these markers were explored by a univariate and multivariate analysis. Survival was analyzed using Kaplan-Meier (OS) and Wilcoxon two-sample (DSS) tests. RESULTS:IDO expression was higher in ER+ tumors compared to ER- tumors. IDO was lower in those with higher neoangiogenesis. OS was better in ER+ patients with high IDO expression. DSS was better in node-positive patients with high IDO expression. IDO activity positively correlates with NOS2. COX2 as positively correlated with IDO on univariate but not multivariate analysis. There was a trend toward greater numbers of CD11b+ cells in IDO-low tumors. CONCLUSIONS:IDO protein expression is lower in ER- breast tumors with greater neoangiogenesis. Future clinical trials evaluating the synergy between IDO inhibitors and chemotherapy should take this finding into account and stratify for ER status in the trial design.
Authors: Sharon A Glynn; Brenda J Boersma; Tiffany H Dorsey; Ming Yi; Harris G Yfantis; Lisa A Ridnour; Damali N Martin; Christopher H Switzer; Robert S Hudson; David A Wink; Dong H Lee; Robert M Stephens; Stefan Ambs Journal: J Clin Invest Date: 2010-10-18 Impact factor: 14.808
Authors: Alexander J Muller; James B DuHadaway; P Scott Donover; Erika Sutanto-Ward; George C Prendergast Journal: Nat Med Date: 2005-02-13 Impact factor: 53.440
Authors: Jocelyne Jacquemier; François Bertucci; Pascal Finetti; Benjamin Esterni; Emmanuelle Charafe-Jauffret; Marie-Laure Thibult; Gilles Houvenaeghel; Benoit Van den Eynde; Daniel Birnbaum; Daniel Olive; Luc Xerri Journal: Int J Cancer Date: 2012-01-01 Impact factor: 7.396
Authors: David H Munn; Madhav D Sharma; Babak Baban; Heather P Harding; Yuhong Zhang; David Ron; Andrew L Mellor Journal: Immunity Date: 2005-05 Impact factor: 31.745
Authors: Robyn L Prueitt; Brenda J Boersma; Tiffany M Howe; Julie E Goodman; Douglas D Thomas; Lei Ying; Candice M Pfiester; Harris G Yfantis; John R Cottrell; Dong H Lee; Alan T Remaley; Lorne J Hofseth; David A Wink; Stefan Ambs Journal: Int J Cancer Date: 2007-02-15 Impact factor: 7.396
Authors: Binzhi Qian; Yan Deng; Jae Hong Im; Ruth J Muschel; Yiyu Zou; Jiufeng Li; Richard A Lang; Jeffrey W Pollard Journal: PLoS One Date: 2009-08-10 Impact factor: 3.240
Authors: Gerald Brandacher; Alexander Perathoner; Ruth Ladurner; Stefan Schneeberger; Peter Obrist; Christiana Winkler; Ernst R Werner; Gabriele Werner-Felmayer; Helmut G Weiss; Georg Göbel; Raimund Margreiter; Alfred Königsrainer; Dietmar Fuchs; Albert Amberger Journal: Clin Cancer Res Date: 2006-02-15 Impact factor: 12.531
Authors: Shane R Thomas; Andrew C Terentis; Hong Cai; Osamu Takikawa; Aviva Levina; Peter A Lay; Mohammed Freewan; Roland Stocker Journal: J Biol Chem Date: 2007-05-29 Impact factor: 5.157
Authors: Satish K Noonepalle; Franklin Gu; Eun-Joon Lee; Jeong-Hyeon Choi; Qimei Han; Jaejik Kim; Maria Ouzounova; Austin Y Shull; Lirong Pei; Pei-Yin Hsu; Ravindra Kolhe; Fang Shi; Jiseok Choi; Katie Chiou; Tim H M Huang; Hasan Korkaya; Libin Deng; Hong-Bo Xin; Shuang Huang; Muthusamy Thangaraju; Arun Sreekumar; Stefan Ambs; Shou-Ching Tang; David H Munn; Huidong Shi Journal: Cancer Immunol Res Date: 2017-03-06 Impact factor: 11.151
Authors: Bohuslav Melichar; Martina Spisarová; Marie Bartoušková; Lenka Kujovská Krčmová; Lenka Javorská; Hana Študentová Journal: Ann Transl Med Date: 2017-07
Authors: Baosheng Chen; David M Alvarado; Micah Iticovici; Nathan S Kau; Haeseong Park; Parag J Parikh; Dinesh Thotala; Matthew A Ciorba Journal: Cancer Immunol Res Date: 2020-03-03 Impact factor: 11.151